Glenmark Pharmaceuticals surged 10% on July 11, hitting a lifetime high after its subsidiary IGI signed a $700 million licensing deal with AbbVie for cancer drug ISB 2001. IGI will receive milestone payments and royalties, while Glenmark retains rights in emerging markets. This deal pushed the stock to a lifetime high, drawing strong investor interest despite a weak broader market.